Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — ESG Presentation (March 2022)
60 slides from Coloplast A/s Class B's sustainability presentation, Mar 22, 2022
Slide 1: Coloplast's virtual ESG event
22 March 2022 Welcome to Coloplast’s Tabitha, UK virtual ESG event Strive25: Sustainable Growth Leadership Making life easier 1 |
Slide 2: Agenda
Coloplast ESG event 2022 Agenda Time Session Speaker 15.00 - 15.05 Opening remarks Ellen Bjurgert - Vice President, Investor Relations Company mission and 15.05 - 15.25 Kristian Villumsen, President & CEO sustainability strategy 15.25 - 15.40 Improving products and packaging Camilla Hjort Pagh, Seni
Slide 3: Company mission and sustainability strategy
Coloplast’s ESG event 22 March 2022 Company mission and sustainability strategy Wanyong, China Kristian Villumsen President & CEO Making life easier 3 |
Slide 4: Making life easier for people with intimate healthcare needs
Making life easier Stina, Sweden for people with intimate healthcare needs 4 |
Slide 5: Katryna, UK Wanyong,
Stina Katryna, Wanyong, Emma, UK China Japan
Slide 6: Tabitha, UK Bob,
Tabitha, Bob, UK US Kristian, Denmark
Slide 7: Waiting for a better resolution picture from Atos (and the
Waiting for a better resolution picture from Atos (and the story). Will call JP Victor, Brian, tomorrow if I don’t Anna, Denmark US Sweden hear back Stina
Slide 8: 2 million users
2 million users
Slide 9: Making life easier for people with intimate healthcare needs
Making life easier for people with intimate Bjarne, healthcare Denmark needs = Self-care 9 |
Slide 10: We are building the consumer healthcare company of the future
We are building the consumer healthcare company of the future Commercial model Superior, clinically differentiated products Tatiana, US Consumer preference Data and Clinical digital tools preference Payer preference 10 |
Slide 11: Sustainability is a core strategic theme during Strive25
Sustainability is a core strategic theme and one of the focus areas during the Strive25 period Chronic Care Interventional Wound & Urology Skin Care 7-9% 7-9% more than30% organic growth p.a. EBIT margin1 Talent, organic growth p.a. Innovation Leadership & Culture Unparalleled Sustainability efficie
Slide 12: Strive25 emphasis on improving environmental performance
With Strive25 we put emphasis on improving our environmental performance, while continuing our ongoing commitments Our mission Making life easier for people with intimate healthcare needs Stina, Sweden Our 2025 priority Our 2025 priority Improving Reducing products and emissions packaging Our on-goi
Slide 13: Innovative products launched across all business areas
With user needs at the centre, Coloplast has launched innovative products across all business areas Ostomy Care Continence Care Wound & Skin Care Interventional Urology 13 |
Slide 14: Committed to clinically differentiated solutions for users' unmet needs
We continue innovating and are committed to delivering clinically differentiated solutions to tackle our users’ unmet needs Our users across business areas continue to be challenged by To address this we continue innovating and will launch new their conditions technologies, as well as products in ex
Slide 15: The Coloplast Professional platform
The Coloplast Professional platform builds a strong connection with healthcare professionals globally Coloplast® Professional Education Masterclasses & events Gain or refresh essential Broaden expertise and knowledge and insights connect with peers Thousands of Healthcare Professionals engaged every
Slide 16: Coloplast Care and DtC support users across countries
Through Coloplast Care and DtC we support users across countries and business areas +2M consumers in our database Yue Zhang, China +3.6M conversations with users across the globe +30 countries with a consumer setup 16 |
Slide 17: Market Development and Access to Healthcare
Through Market Development initiatives and Access to Healthcare we continue to increase standards of care across the globe Market Development efforts are focused on creating access Through our Access to Healthcare for more users program we seek to improve quality of care across our business areas 1
Slide 18: Atos Medical's sustainability themes aligned with Coloplast
Atos Medical’s sustainability themes are closely aligned with Coloplast’s approach to sustainability Atos Medical is focused on increasing the While reducing the environmental number of patients served… impact of its products and activities Key focus area #1: Key focus area #2: 2X number of customer
Slide 19: People and culture at the heart of Strive25
At the heart of delivering on our Strive25 strategy are our people and culture People & Culture Evolving how we lead Adriana, Brazil Talent for future Inclusion & Diversity 19 |
Slide 20: Improving products and packaging
Coloplast’s ESG event 22 March 2022 Improving products and packaging Camilla Hjort Pagh SVP, Global QA, RA & Sustainability Making life easier 20 |
Slide 21: Strengthened and clear governance of sustainability
We have a strengthened and clear governance of Sustainability Board of Directors Remuneration and Nomination Committee Consists of six shareholder-elected and three Consists of four members appointed among employee-elected members. the Board of Directors. Executive Leadership Team Audit Committee Co
Slide 22: Sustainability is a core element of Strive25
Sustainability is a core element of our Strive25 strategy, with a strong focus on improving our environmental performance Our mission Chronic Care Making life easier for people with intimate healthcare needs Interventional Wound & Urology Skin Care Our 2025 priority Our 2025 priority Improving produ
Slide 23: Safe and healthy work environment for employees
Providing a safe and healthy work environment for employees is a core focus for Coloplast SafePlan (2.0) was launched to continue the focus on Global crisis, such as COVID-19, are managed by a safety behaviours globally along with a target to reduce global task force, and employee health and safety
Slide 24: Unified global quality management system
Our mission to deliver safe and reliable products is supported by a unified global quality management system Standards: uniform global processes to manage quality and risks throughout product development, production and distribution as well as post-market surveillance Our quality management system l
Slide 25: Medical Device Regulation compliance
Medical Device Regulation (MDR) compliance enables license to operate & sell; 75% of Coloplast revenue is MDR compliant* Objective of MDR: Products are safe and can be Main changes from MDD to MDR: Increased focus freely and fairly traded throughout the EU on clinical evidence, Post Market Surveilla
Slide 26: Focus on eco-design and recyclability
We have an increased focus on eco-design and recyclability, without compromising product safety and performance As a manufacturer of medical products made of plastic, Coloplast has a responsibility to contribute to solving the plastic waste problems. We embrace that responsibility and have set clear
Slide 27: Mindful selection of materials and substances
Coloplast is mindful when selecting the materials and substances used in our products • Coloplast products are biocompatible and safe for the intended purpose. • We comply with international and local regulations and standards – including REACH, the California proposition 65 list, EU MDR, FDA, the E
Slide 28: Integrating sustainability in innovation through eco-design
Integrating sustainability in Innovation by including eco-design criteria to achieve a sustainable pipeline Chemicals Material type Size and weight Recyclability Climate impact Production waste 28 |
Slide 29: Improving products and packaging by addressing material use
Our 2025 priority: Improving products and packaging Improving products and packaging by addressing material use Our secondary and tertiary packaging is already made of Ongoing packaging projects include converting PET renewable materials. Focus is on redesigning primary plastic trays to recycled PET
Slide 30: Value chain footprint
Coloplast’s ESG event 22 March 2022 Value chain footprint Nassera Ahmed Senior Director Sustainability Making life easier 30 |
Slide 31: Industry partnerships for new materials and technologies
Industry partnerships are essential to meet our ambition of identifying new materials and support development of new technologies To advance recycling technologies and circular products, Coloplast has entered an applied research partnership together with Danish Technological Institute and other part
Slide 32: Waste recycling partnership in Hungary
Waste recycling partnership has been established in Hungary increasing our production waste recycling rate to 65%* 32 | *Data from Q1 21/22
Slide 33: Science-based climate action for a 1.5°C future
Coloplast is committed to ambitious science-based climate action for a 1.5°C future 33 |
Slide 34: Reducing emissions while being a growth company
Our 2025 priority: Reducing emissions We are committed to reducing emissions while being a growth company 2025 target – Scope 1+2 Net-zero Scope 1 & 2 - Natural Scope 3 – Other reported gas and company cars • 100% Renewable energy (PPAs 9% 13% and phase out natural gas use) • 50% of company cars are
Slide 35: Aiming for 100% renewable energy use by 2025
Coloplast aims to achieve 100% renewable energy use by 2025 • 67% of energy used by Coloplast is from renewable sources • 100% renewable electricity is used based on the purchased renewable energy certificates • We will enter into Power Purchase Agreements (PPAs) covering all production sites and re
Slide 36: Supplier Sustainability Program
Supplier Sustainability Program Searching for Better recycling Strengthening and developing of raw materials supplier base to materials with and production improve footprint lower impact waste Monitoring of Improved Ensuring high direct and production standards and indirect practices compliance supp
Slide 37: Climate risk is financial risk: TCFD recommendations
Climate risk is financial risk and thus we support the TCFD recommendations We support the TCFD recommendations and have decided All stakeholders Company impact to take a step-by-step approach to report according to the interested in on climate TCFD framework and will step-wise increase our disclosu
Slide 38: Q&A Session
Coloplast’s ESG event 22 March 2022 Kristian, Denmark Q&A Session Camilla Hjort Pagh, SVP, Global QA, RA & Sustainability Nassera Ahmed, Senior Director Sustainability Making life easier 38 |
Slide 39: Governance and key risks
Coloplast’s ESG event 22 March 2022 Governance and key risks Kirsten, Denmark Anders Lonning-Skovgaard Executive Vice President, CFO Making life easier 39 |
Slide 40: Two-tier management structure: Board and Executive Leadership Team
Coloplast has a two-tier management structure comprising the Board of Directors and the Executive Leadership Team Governance structure Composition of Board of Directors Audit Rem. & Nomin. Board member Nationality Gender Independent Committee Committee Lars Rasmussen, Chairman1 Danish Male No Niels
Slide 41: Organisation divided into Chronic Care and Strategic Business Units
The Coloplast organisation is divided into Chronic Care and Strategic Business Units, running on shared global business support functions Coloplast Group Chronic Care Strategic Business Unit Wound Interventional Voice & Respiratory Ostomy Care Continence Care & Skin Care Urology Care Marketing Marke
Slide 42: Standardised risk reporting and governance process
We have a standardised risk reporting and governance process, involving the Board of Directors and Executive Leadership Team Risk governance structure Key risk categories for Coloplast over a five-year horizon* Board of Directors Monitors overall risk landscape Impact Reviews conclusions and recomme
Slide 43: ESG reporting and external standards
ESG reporting is defined by external standards and requirements, and ESG related metrics are reported on a regular basis Our disclosures and reporting of ESG metrics is Reporting of ESG metrics is now done on a quarterly defined by external standards basis2 EU Taxonomy Rankings performed by third-pa
Slide 44: Business ethics and compliance
Coloplast’s ESG event 22 March 2022 Business ethics Emma, Japan and compliance Megan Olson-Lehner Group Chief Compliance Officer Making life easier 44 |
Slide 45: Global Business Ethics & Compliance function
Business Ethics & Compliance is a global function with oversight from the Executive Leadership Team and Board of Directors Coloplast Board of Directors Coloplast Audit Committee Executive Leadership Team Group Chief Compliance Officer Region Asia Region Emerging Markets Region Europe Region North Am
Slide 46: Behavior guided by laws, industry codes and Code of Conduct
Our company behavior is guided by external laws and industry codes, as well as internal policies and Code of Conduct External Internal Guiding principles: • Always follow the strictest requirement • Protect Coloplast brand and reputation • Always consider the perception of our actions and decisions
Slide 47: Business Ethics & Compliance Strive25 strategy
The Business Ethics & Compliance Strive25 strategy is focused on building a strong foundation and supporting growth Business Ethics Foundation & Compliance Growth Empower Employees Utilize interactive learning strategies Invest in Talent Empower Employees Empowering and developing compliance employe
Slide 48: Compliance programme with eight key elements
Coloplast runs an extensive and standardized compliance programme with eight key elements 1 Compliance Officer & Governance 5 Reporting & Investigating 2 Standards of Conduct 6 Enforcement & Discipline 3 Education 7 Response & Prevention 4 Monitoring & Auditing 8 Compliance Risk Assessments Leadersh
Slide 49: Global Ethics Hotline
Coloplast has a global Ethics Hotline, where employees can report suspected breaches of the Coloplast BEST Code of Conduct Ethics Hotline reports by region in FY 2020/21 Europe North America 14 reports Asia 11 reports 9 reports Benchmark case volumes FY 2020/21 (average) Coloplast 4.9 reports/1,000
Slide 50: Ethics reports have gone down
Ethics reports have gone down, and majority of cases are reported through the hotline or line management Total case volumes Case intake FY 2020/21 78 34 Cases out of scope 15 61 25 29 Cases within scope 63 32 2 2019/20 2020/21 Monitoring Ethics Hotline Line Management 50 |
Slide 51: Protecting personal data under national laws
In a complex and evolving regulatory environment, Coloplast handles and protects personal data in accordance with national laws UK EU UK GDPR EU GDPR CHINA New privacy law US (PIPL) US Privacy Laws + HIPAA BRAZIL New privacy law NEW ZEALAND (LGPD) New privacy law Data management • Data privacy and s
Slide 52: Group Data Protection Officer
A Group Data Protection Officer within Coloplast is fully dedicated to data privacy and supported by local privacy representatives SVP, Group General Counsel Data privacy board Group DPO SVP, Group CIO Head of Global Information Security Director HR Data Analytics Senior Director, VP, Digital Consum
Slide 53: Information Security
Coloplast’s ESG event 22 March 2022 Information Victor, Security Denmark René Rasmussen CIO & SVP Information Technology Making life easier
Slide 54: The Information Security threat landscape is constantly evolving
The Information Security threat landscape is constantly evolving Complex, criminally motivated Used for credential stealing • Multiple threat patterns e.g., social attack • Threat vector for malware or system and malware or social attack and hacking intrusion actions via stolen credentials • Phishin
Slide 55: Key trends in healthcare and manufacturing
Coloplast is categorized as both healthcare and manufacturing, where a number of key trends have emerged Industry comparison Similarities Differences • Shared threat actor motivation: financial, espionage, and grudge • Basic human error continues to impact the healthcare industry • Ransomware is a f
Slide 56: Information Security governance set-up
At Coloplast the Governance set-up for Information Security has evolved to adapt to the rapidly changing external environment Audit Committee Board of Directors Oversight (Annually) (Annually) Executive Anders Lonning-Skovgaard CFO René Rasmussen Management CIO & SVP Information Technology Head of G
Slide 57: Risk-based approach to information security
Strategy and Governance for Information Security is centred around a risk-based approach Threats Objective: Enhance ability to detect, Compliance Objective: Ensure compliance to relevant respond & recover & Regulations regulations and laws • Physical security perimeter controls • ISO 27001 certifica
Slide 58: Information Security Policy – our position
Information Security Policy – our position Coloplast’s focus on sustainable innovation and growth requires us to operate in a dynamic information risk environment. It is therefore essential that we maintain proper controls to ensure our environment is protected from external and internal threats, un
Slide 59: Q&A Session
Coloplast’s ESG event 22 March 2022 Q&A Session Megan Olson-Lehner, Group Chief Compliance Officer René Rasmussen, CIO & SVP Information Technology Making life easier 59 |
Slide 60: Closing remarks
Coloplast’s ESG event 22 March 2022 Closing Katryna, UK remarks Ellen Bjurgert Vice President, Investor Relations Making life easier 60 |